New York, USA – 24th October 2025 – GPN Vaccines Inc (“GPN”) is pleased to announce it has successfully completed the acquisition of BacVax Inc. (“BacVax”), a biotechnology company based in Phoenix, Arizona, that is developing vaccines targeting bacterial infections.
The acquisition further increases GPN’s footprint in the United States and builds the company’s pipeline through a suite of complementary products, along with expertise and resources for the development of bacterial vaccines, where there is a clear unmet need.
The BacVax opportunity includes products designed to prevent exacerbations associated with chronic obstructive pulmonary disease (COPD), a market worth of US$40 billion per annum, as well as vaccines for otitis media infections in infants and children. Further, BacVax holds an Exclusive Patent License Agreement to use the Bacterial Vaccine Polypeptide (BVP) platform, complemented by additional patent applications targeting bacterial pathogens.
The decision to acquire BacVax comes after a successful research collaboration between the two companies, and a shared vision to advance global vaccine innovation.
This strategic decision follows GPN’s recent move to the US, and reinforces the company’s commitment to accelerating its vaccine development pipeline.
Prof. Tim Hirst, Chairman and CEO of GPN Vaccines Inc, stated:
“This acquisition marks an important milestone in GPN’s growth strategy. By combining complementary technologies and expertise, we are strengthening our ability to deliver innovative vaccines to help solve some of the world’s most serious health problems. I am delighted by the opportunities this acquisition will bring.”
Dr. Terrence Stull, M.D., President and Founder of BacVax Inc., commented:
“We are thrilled to be joining forces with GPN Vaccines. The combination of our scientific platforms and GPN’s robust development capabilities will enable us to bring innovative bacterial vaccines to the world.”
About GPN Vaccines Inc
GPN Vaccines Inc is a clinical stage Delaware C-corporation developing vaccines against innovative bacterial vaccines, with its lead vaccine targeting Streptococcus pneumoniae. S. pneumoniae is responsible for causing life-threatening pneumonia, bacteraemia and meningitis, as well as otitis media (middle ear infections) and each year causes 1-2 million deaths worldwide, killing more children than AIDS, malaria and tuberculosis combined. There are now more than 100 different serotypes of S. pneumoniae and the best vaccine currently on the market only protects against 21 of them. GPN Vaccines’ product, called Gamma-PNTM, is being developed to protect children and adults against all S. pneumoniae strains, regardless of serotype.
About BacVax Inc.
BacVax Inc. is a vaccine research and development company headquartered in Phoenix, Arizona. The company specializes in designing and developing vaccines against bacterial pathogens, leveraging its proprietary Bacterial Vaccine Polypeptide (BVP) platform. BacVax holds Exclusive Patent Licensing Agreement with the University of Arizona to use this platform. This platform can be applied to create vaccine against human and animal diseases.
Media Contacts
Tim Hirst
Chief Executive Officer, GPN Vaccines Inc
tim@gpnvaccines.com
+61 420 942 824
Terrence Stull, M.D.
President & Founder of BacVax Inc.
tlstill@bacvax.com
+1 405 488 5919
SOURCE: https://gpnvaccines.com/gpn-vaccines-inc-completes-acquisition-of-bacvax-inc/